tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

URGN Stock Latest News

UroGen Pharma Shareholders Approve Key Proposals at Meeting
Company AnnouncementsUroGen Pharma Shareholders Approve Key Proposals at Meeting
11d ago
8K
URGN
Piper starts ‘underestimated’ UroGen Pharma with an Overweight
PremiumThe Fly
Piper starts ‘underestimated’ UroGen Pharma with an Overweight
20d ago
URGN
UroGen Pharma initiated with an Overweight at Piper Sandler
PremiumThe Fly
UroGen Pharma initiated with an Overweight at Piper Sandler
20d ago
URGN
UroGen Pharma’s Earnings Call: Achievements and Challenges
PremiumCompany Announcements
UroGen Pharma’s Earnings Call: Achievements and Challenges
26d ago
URGN
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
28d ago
URGN
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
PremiumCompany AnnouncementsUroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
1M ago
URGN
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
Premium
Ratings
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
1M ago
URGN
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
Premium
The Fly
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
1M ago
URGN
UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
PremiumThe Fly
UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
1M ago
URGN
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
PremiumThe Fly
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
1M ago
URGN
UroGen Pharma announces five-year long-term extension study of ZUSDURI
PremiumThe Fly
UroGen Pharma announces five-year long-term extension study of ZUSDURI
2M ago
URGN
UroGen Pharma call volume above normal and directionally bullish
PremiumThe Fly
UroGen Pharma call volume above normal and directionally bullish
2M ago
URGN
UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals
PremiumRatingsUroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals
2M ago
URGN
UroGen Pharma completes enrollment in Phase 3 UTOPIA trial of UGN-103
Premium
The Fly
UroGen Pharma completes enrollment in Phase 3 UTOPIA trial of UGN-103
2M ago
URGN
UroGen Pharma Approves Bonuses After FDA Approval
Premium
Company Announcements
UroGen Pharma Approves Bonuses After FDA Approval
2M ago
8K
URGN
Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts
PremiumWeekend Updates
Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts
3M ago
SG
ALGM
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
3M ago
CEP
RDW
UroGen Pharma upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
UroGen Pharma upgraded to Buy from Neutral at H.C. Wainwright
3M ago
URGN
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
PremiumThe Fly
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
3M ago
URGN
UroGen Pharma price target raised to $31 from $10 at Oppenheimer
PremiumThe FlyUroGen Pharma price target raised to $31 from $10 at Oppenheimer
3M ago
URGN
UroGen Pharma price target raised to $47 from $23 at Scotiabank
Premium
The Fly
UroGen Pharma price target raised to $47 from $23 at Scotiabank
3M ago
URGN
FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer
Premium
Company Announcements
FDA Approves Urogen Pharma’s ZUSDURI for Bladder Cancer
3M ago
8K
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >